Guang Yuyuan, once a traditional Chinese medicine "demon stock", has finally ushered in a rising momentum after a substantial adjustment, and continues to hit the limit today after yesterday's limit.
Wearing a wide reputation of two major concepts
Guangyuyuan's share price has experienced a roller coaster in recent months. For its hype, it began with the difficulty of finding a tablet of Pian Tsai Yi, and then Yunnan Baiyao was also hyped, and then the market began to look for relatively undervalued stocks of traditional Chinese medicine, and the wide reputation was speculated by funds under this background.
Similar to Yunnan Baiyao and Panzi Pian Tzu, Guilingji and Dingkundan have two state secret prescriptions and three national intangible cultural heritage production processes of traditional Chinese medicine.
In addition, at that time, with the intensive introduction of favorable policies to revitalize the traditional Chinese medicine industry, the wide reputation stood on the tuyere for a while, and the stock price continued to hit new highs.
In addition, it should be pointed out that Guanyuyuan has been included in the liquor sector by the market because of its health wine business. This is also a big reason why its share price has risen before.
However, for being included in the concept of liquor, Guangyuyuan has issued a notice saying that the company is mainly engaged in the production and sales of traditional Chinese medicine products, and its core business is proprietary Chinese medicine business. The main products of the health-preserving wine plate are modified Guilingji wine and Guilingji health wine. In 2020, the operating income of health-preserving wine accounts for only 3% of the company's operating income, which will not have a significant impact on the company's operating performance.
It is difficult to accept the poor performance of the report.
There are two main reasons for the sharp adjustment after Guanyuyuan's share price.
First, the low tide of speculation, coupled with the switching of market style, the adjustment of liquor and medicine has lasted for a long time.
Second, Guangyuyuan's performance is unexpectedly poor. According to the China News, the company's operating income in the first half of the year was 375 million yuan, down 13.22% from the same period last year; the corresponding attributable net profit was-48.0839 million yuan, down 210.69% from the same period last year.
With the rebound of Guanyuyuan's share price, some investors should have lifted the lock-up, but for those investors who rush into the high position, it will take time to release the lock-up.